Epigallocatechin-3-gallate inhibits interleukin-6- and angiotensin II-induced production of C-reactive protein in vascular smooth muscle cells

Ning Peng [a,b], Jun-tian Liu [a,*], Fang Guo [a], Rui Li [b]

[a] Department of Pharmacology, Xi'an Jiaotong University School of Medicine, Xi'an, China
[b] People's Hospital of Shaanxi Province, Xi'an, China

ARTICLE INFO

ABSTRACT

Aims: Extensive research suggests that atherosclerosis is an inflammatory disease and that epigallocatechin-3-gallate (EGCG) is able to inhibit the formation and development of atherosclerosis. However, the mechanisms of action of EGCG against atherosclerosis are still unclear. Therefore, the effect of EGCG on interleukin-6 (IL-6)- and angiotensin II (Ang II)-induced CRP production in vascular smooth muscle cells (VSMCs) was studied to provide experimental evidence for its anti-inflammatory and anti-atherosclerotic actions.

Main methods: Rat VSMCs were cultured, and IL-6 (10^{-7} M) and Ang II (10^{-7} M) were used as stimulants for CRP generation. The CRP concentration in the supernatant was measured with ELISA, and mRNA and protein expression of CRP was assayed with RT-qPCR and immunocytochemistry, respectively. The production of reactive oxygen species (ROS) and superoxide anion (O_2^-) was detected with ROS and O_2^- assay kits, respectively.

Key findings: The results showed that both IL-6 and Ang II increased CRP levels in the supernatant of VSMCs and induced mRNA and protein expression of CRP in VSMCs, whereas pretreatment of the cells with EGCG (1×10^{-6} M, 3×10^{-6} M, 10×10^{-6} M) significantly inhibited IL-6- and Ang II-induced production and expression of CRP in VSMCs in a concentration-dependent manner. Additionally, Ang II stimulated O_2^- and ROS generations in VSMCs, and EGCG decreased the Ang II-induced increase of O_2^- and ROS in a concentration-dependent fashion.

Significance: These results suggest that EGCG plays an anti-inflammatory role via inhibiting IL-6- and Ang II-induced CRP secretion, as well as the Ang II-induced generation of O_2^- and ROS in VSMCs, which contributes to its anti-atherosclerotic action.

Introduction

The inflammatory response plays an important role in the onset, development and evolution of atherosclerotic lesions (Libby 2002). As an exquisitely sensitive marker of inflammation, C-reactive protein (CRP) has emerged as an important predictor of cardiovascular events (Jialal et al. 2004; Danesh et al. 2004). Large studies support the proatherogenic effects of CRP via injuring endothelial cells, promoting monocyte–macrophage accumulation, and stimulating the migration and proliferation of vascular smooth muscle cells (VSMCs). Further investigations have shown that CRP causes the expression of monocyte chemoattractant protein-1, interleukin-6 (IL-6) and induc-

ible nitric oxide synthase through activating the MAPK-c-Fos/c-Jun-AP-1 pathway in VSMCs. Recently, a study also showed that human coronary artery smooth muscle cells are able to generate CRP after being stimulated with inflammatory cytokines (IL-1β, IL-6 and tumor necrosis factor-α), which raises the possibility that human coronary artery smooth muscle cells may be a source of locally produced CRP in the arterial wall (Calabró et al. 2003). Our previous study also found that angiotensin II (Ang II) is capable of inducing CRP generation in VSMCs, which strengthens the role of Ang II in the inflammatory process in atherosclerosis (Peng et al. 2007). Additionally, Ang II can induce the generation of reactive oxygen species (ROS) and superoxide anion (O_2^-). As signaling molecules, ROS play crucial roles not only in Ang II-mediated pathophysiological processes, but also in atherosclerosis via mediating specific cellular responses, such as CRP and IL-6 generation (Griendling et al. 2000).

Epigallocatechin-3-gallate (EGCG), mainly contained in green tea and red wine, has received attention as a prospective dietary

* Corresponding author. Postbox 58, Xi'an Jiaotong University School of Medicine, 76 West Yanta Road, Xi'an 710061, P. R. China. Tel./fax: +86 29 82655188.
E-mail address: ljt@mail.xjtu.edu.cn (J. Liu).

intervention in cardiovascular diseases (Zaveri 2006; L'Allemain 1999; Miura et al. 2000). Experimental studies have confirmed that green tea catechins reduce atherosclerotic lesions in animal models of hyperlipidemia (Chyu et al. 2004), and that EGCG suppresses the migration of human VSMCs and the low-density lipoprotein-induced proliferation of rat VSMCs. In addition, EGCG prevents pathogenesis of cardiovascular diseases by acting as a scavenger of ROS (Wei et al. 2004; Cheng et al. 2005). Our past work also demonstrated that EGCG possesses an anti-inflammatory property in microglial cells (Li et al. 2006). Since chronic inflammation in the artery wall plays a central role in atherogenesis, we hypothesized that EGCG possibly produces an anti-inflammatory effect on vascular cells. Hence, the present study observed the inhibitory effects of EGCG on the IL-6- and Ang II-induced generation of CRP in VSMCs.

Materials and methods

Reagents

Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin, streptomycin and Trizol reagents were purchased from GIBCO BRL (Carlsbad, CA, USA). IL-6 was from R&D systems (USA). Ang II and EGCG were from Sigma (USA). The rat CRP ELISA kit was produced by Alpha Diagnostics International (San Antonio, TX, USA). CRP antibody, α-actin antibody and the ABC kit for immuno-cytochemical staining were obtained from Beijing Biosynthesis Biotechnology Co., LTD (Beijing, China). The ROS and superoxide anion assay kits were purchased from the Beyotime Institute of Biotechnology (Shanghai, China).

Cell culture

VSMCs were isolated from the thoracic aorta of Sprague–Dawley rats as described previously (Griendling et al. 1991) and maintained in DMEM supplemented with 10% FBS, 100 U/mL penicillin and 100 U/mL streptomycin at 37 °C in a humidified atmosphere of 95% air and 5% CO_2 until the cells exhibited the typical "hill and valley" growth morphology. Then, the cells were verified by immunocytochemical staining for α-actin. VMSCs at passage 3–10 were used for the experiments. The culture medium was changed to DMEM supplemented with 0.1% FBS for an additional 24 h before the experiments.

Enzyme-linked immunosorbent assay (ELISA)

Confluent VSMCs grown in 6-well plates were pretreated with different concentrations of EGCG (1×10^{-6} M, 3×10^{-6} M, 10×10^{-6} M) for 30 min and stimulated by IL-6 (10^{-7} M) or Ang II (10^{-7} M) for 24 h. Then, the conditioned medium was collected and concentrated (~20 fold) using centrifugal filter units (Millipore, Bedford, MA, USA), and the CRP concentration was assayed by an ELISA kit specific for rat CRP according to the manufacturer's instructions.

Real-time quantitative polymerase chain reaction (RT-qPCR)

The mRNA level of CRP was quantitatively measured by RT-qPCR. In brief, total cellular RNA was extracted by the Trizol reagent and quantified by measuring the absorbance at 260 and 280 nm. The total RNA purity (A_{260}/A_{280}) was between 1.6 and 1.9. The quality of RNA was confirmed by ethidium bromide staining after 1% agarose gel fractionation. Complementary DNA (cDNA) was synthesized from 1 μg of total RNA by using the Revert Aid™ First Strand cDNA synthesis kit (Fermentas, St. Leon-Rot, Germany) following the manufacturer's protocol. Real-time polymerase chain reaction with SYBR was performed with a SuperScript™III Platinum® Two-Step qRT-PCR kit (Invitrogen, USA) on an ABI Prism 7000 sequence detection PCR system (Applied Biosystems, CA, USA) according to the manufacturer's

instructions. Specific cDNA from the reverse transcriptase reaction product was amplified using a primer pair specific for rat CRP (sense primer: 5′-CACAACAGTCAGTCAAGG-3′, antisense primer: 5′-GTGCTATCTCCAGAACAG-3′), which yielded a fragment of 142 bp. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cDNA served as an internal control (sense primer: 5′-GCCTTCTCCATGGTGGTGAA-3′, antisense primer: 5′-GGTCGGTGTGAACGGATTTG-3′). The reaction conditions were 2 min at 50 °C, 2 min at 95 °C, 15 s at 95 °C, 30 s at 52 °C, and 30 s at 72 °C for 45 cycles. In all of the experiments, control reactions were performed by substituting sterile nuclease-free water for the RNA template in the reaction. The specificity of the RT-PCR products was confirmed by melting curves and visualization on 1% TAE agarose gel with ethidium bromide staining. The relative amount of each mRNA was normalized to the housekeeping gene (GAPDH) mRNA. Quantitative data of relative gene expression were determined by the comparative Ct method ($2^{-\Delta\Delta Ct}$), as described by the manufacturer.

Immunocytochemical staining

The stimulated VSMCs were moved to cover slips and mounted on slides. All of the slides were immersed in 3% H_2O_2 in methanol for 45 min at room temperature to block the activity of endogenous peroxidases. The sections were then incubated with 10% normal goat serum for 1.5 h and reacted with CRP antibody (1:300) overnight at 4 °C. After being washed several times with phosphate-buffered saline (pH 7.4), the sections were incubated with peroxidase-conjugated secondary antibody for 60 min at room temperature. The immunological staining was developed with an ABC kit.

Measurement of intracellular ROS and O_2^-

ROS generation in VSMCs was monitored with the oxidation-sensitive fluorescent probe 2′,7′-dichlorodihydrofluorescein diacetate (H_2DCF-DA), as previously described (Bass et al. 1983). In brief, subconfluent VSMCs were seeded on poly-L-lysine coated glass cover slips (8×8 mm) in 24-well plates and incubated for 20 min at 37 °C with 10^{-5} M H_2DCF-DA in serum-free medium. Then, the cells were pretreated with different concentrations of EGCG (1×10^{-6} M, 3×10^{-6} M, 10×10^{-6} M) for 30 min before being stimulated with Ang II (10^{-7} M). Subsequently, the cells were imaged with a laser scanning confocal microscope (Leica TCS SP2, Germany) in a dark environment every 2 min for 10 min after the specimen was mounted on the object stage. Fluorescence images were acquired at excitation and emission wavelengths of 488 and 525 nm, respectively. The fluorescence intensity of an experimental field comprising 15–20 cells of each group was measured and analyzed with Image-pro plus software. The relative fluorescence intensity was taken as the average of values from four repeated experiments.

Intracellular O_2^- was detected using a superoxide anion assay kit from the Beyotime Institute of Biotechnology (Shanghai, China), which is based on O_2^- deoxidizing WST-1[2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium] to a soluble and colored substance showing an absorbance at 450 nm. Confluent VSMCs grown in 96-well plates were pretreated with different concentrations of EGCG (1×10^{-6} M, 3×10^{-6} M, 10×10^{-6} M) for 30 min prior to stimulation with Ang II (10^{-7} M). Then, the cells were washed with PBS, and 200 μL of O_2^- assay working solution was added into the cells for further incubation for 3 min at 37 °C according to the manufacturer's instructions. Next, phorbol myristate acetate was added to stimulate the cells for 30 min. Finally, the absorbance was detected at 450 nm every 2 min for 10 min.

Statistical analysis

All values are expressed as mean ± S.D. Statistical significance between groups was assessed by using one-way ANOVA, followed by

Fig. 1. Effect of EGCG on IL-6-induced CRP generation in VSMCs. VSMCs were pretreated with different concentrations of epigallocatechin-3-gallate (EGCG) for 30 min before exposure to 10^{-7} M interleukin-6 (IL-6) for 24 h. Then, the CRP concentration in the supernatant was measured by ELISA. Data are presented as mean ± S.D. of three independent experiments. *$P < 0.05$, **$P < 0.01$ vs. IL-6 alone.

Fisher's exact test. A probability value of $P < 0.05$ was considered to be statistically significant.

Results

Effect of EGCG on IL-6- and Ang II-induced CRP generation in VSMCs

The results in Figs. 1 and 2 showed that CRP in the culture supernatant was markedly elevated after the exposure of VSMCs to 10^{-7} M IL-6 or Ang II for 24 h ($P < 0.05$ or $P < 0.01$ vs. control). However, pretreatment of the cells with different concentrations of EGCG for 30 min prior to IL-6 or Ang II stimulation significantly inhibited IL-6- and Ang II-induced CRP production in a concentration-dependent manner ($P < 0.05$ or $P < 0.01$ vs. IL-6 or Ang II alone).


Fig. 3. Effect of EGCG on IL-6-induced mRNA expression of CRP in VSMCs. VSMCs were pretreated with different concentrations of epigallocatechin-3-gallate (EGCG) for 30 min before exposure to 10^{-7} M interleukin-6 (IL-6) for 24 h. Then, the total RNA of the cells was extracted with the Trizol agent followed by reverse transcription to obtain cDNA. The quantity of cDNA from 1 µg of total RNA was analyzed with SYBR Green-based real-time PCR, and GAPDH was used as a reference for quantification. Quantitative data of relative CRP mRNA were achieved by the comparative Ct method ($2^{-\Delta\Delta Ct}$). Data are presented as mean ± S.D. of three independent experiments. *$P < 0.05$, **$P < 0.01$ vs. IL-6 alone.

Effect of EGCG on IL-6- and Ang II-induced mRNA expression of CRP in VSMCs

CRP mRNA expression in VSMCs was assayed by RT-qPCR. As shown in Figs. 3 and 4, the level of CRP mRNA in VSMCs was also markedly increased following exposure of the cells to 10^{-7} M IL-6 or Ang II for 24 h ($P < 0.01$ vs. control). After the cells were preincubated with different concentrations of EGCG for 30 min, IL-6- and Ang II-induced mRNA expression of CRP was significantly


Fig. 2. Effect of EGCG on Ang II-induced CRP production in VSMCs. VSMCs were pretreated with different concentrations of epigallocatechin-3-gallate (EGCG) for 30 min before exposure to 10^{-7} M angiotensin II (Ang II) for 24 h. Then, the CRP concentration in the supernatant was measured by ELISA. Data are presented as mean ± S.D. of three independent experiments. *$P < 0.05$ vs. Ang II alone.

Fig. 4. Effect of EGCG on Ang II-induced mRNA expression of CRP in VSMCs. VSMCs were pretreated with different concentrations of epigallocatechin-3-gallate (EGCG) for 30 min before exposure to 10^{-7} M angiotensin II (Ang II) for 24 h. Then, the total RNA of the cells was extracted with the Trizol agent followed by reverse transcription to obtain cDNA. The quantity of cDNA from 1 µg total RNA was analyzed with SYBR Green-based real-time PCR, and GAPDH was used as a reference for quantification. Quantitative data of relative CRP mRNA were achieved by the comparative Ct method ($2^{-\Delta\Delta Ct}$). Data are presented as mean ± S.D. of three independent experiments. *$P < 0.05$, **$P < 0.01$ vs. Ang II alone.

Fig. 5. Effect of EGCG on IL-6-induced protein expression of CRP in VSMCs. VSMCs were pretreated with different concentrations of epigallocatechin-3-gallate (EGCG) for 30 min before exposure to 10^{-7} M interleukin-6 (IL-6) for 24 h. Then, CRP expression in VSMCs was detected with immunocytochemical staining. (a) control, (b) IL-6 alone, (c) IL-6 + 1×10^{-6} M EGCG, (d) IL-6 + 3×10^{-6} M EGCG, and (e) IL-6 + 10×10^{-6} M EGCG. Scale bar = 100 μm.

down-regulated in a concentration-dependent manner ($P < 0.05$ or $P < 0.01$ vs. IL-6 or Ang II alone). The experiment also demonstrated that EGCG alone did not affect the mRNA expression of CRP (data not shown).

Effect of EGCG on IL-6- and Ang II-induced protein expression of CRP in VSMCs

CRP protein expression in VSMCs was observed by immunocyto-chemical staining. As seen in Figs. 5 and 6, there was a weakly positive


Fig. 6. Effect of EGCG on Ang II-induced protein expression of CRP in VSMCs. VSMCs were pretreated with different concentrations of epigallocatechin-3-gallate (EGCG) for 30 min before exposure to 10^{-7} M angiotensin II (Ang II) for 24 h. Then, CRP expression in VSMCs was detected with immunocytochemical staining. (a) Control, (b) Ang II alone, (c) Ang II + 1×10^{-6} M EGCG, (d) Ang II + 3×10^{-6} M EGCG, and (e) Ang II + 10×10^{-6} M EGCG. Scale bar = 100 μm.

staining of CRP in control VSMCs (Figs. 5a and 6a). Stimulation of the cells with 10^{-7} M IL-6 or Ang II for 24 h elicited a strong positive staining of CRP in VSMCs (Figs. 5b and 6b). Compared with the IL-6 or Ang II group, EGCG reduced CRP protein expression in VSMCs in a concentration-dependent manner (Figs. 5c, d, e and 6c, d, e).

Effect of EGCG on Ang II-induced O_2^- and ROS in VSMCs

As shown in Fig. 7, 10^{-7} M Ang II induced the generation of O_2^- and ROS in VSMCs in a time-dependent manner. Pretreatment of the cells with different concentrations of EGCG for 30 min prior to Ang II stimulation significantly inhibited Ang II-induced O_2^- and ROS generation in a concentration-dependent manner.

Discussion

As inflammation is involved in all stages of atherosclerosis, CRP, as an inflammatory mediator, may contribute to atherogenesis by activating VSMCs (Hattori et al. 2003). Data from two large trials suggest that statin therapy may lower CRP levels and the risk of cardiovascular events, which is independent of the statin's effect on

a

b

Fig. 7. Effect of EGCG on Ang II-induced O_2^- and ROS generation in VSMCs. VSMCs were pretreated with different concentrations of epigallocatechin-3-gallate (EGCG) for 30 min before exposure to 10^{-7} M angiotensin II (Ang II). Then, reactive oxygen species (ROS) and superoxide anion (O_2^-) were detected with ROS and O_2^- assay kits, respectively. Data were presented as mean ± S.D. of four independent experiments. (a) Effect of EGCG on Ang II-induced ROS generation in VSMCs, and (b) effect of EGCG on Ang II-induced O_2^- generation in VSMCs.

hyperlipidemia (Koenig 2005). Thus, CRP is a potential target for anti-atherosclerotic drugs.

During the last decade, the traditional conception that green tea consumption benefits health has received great scientific attention, particularly in the areas of cardiovascular diseases. EGCG, one of the main constituents of green tea, is considered to be a major contributor to green tea's bioactivity. Recent experiments have shown that EGCG exhibits wide pharmacological activity, such as antioxidation, decreasing blood lipids and serum CRP level in rats, relieving atherosclerotic lesions in various animal models of hyperlipidemia, and suppressing the migration and proliferation of VSMCs (Chyu et al. 2004; Cheng et al. 2005; Ouyang et al. 2004; Ramesh et al. 2010). In this study, we found that EGCG reduced IL-6- and Ang II-induced CRP generation in VSMCs at both the protein and mRNA levels, thereby identifying a possible mechanism for its anti-inflammatory role in the vascular wall. The additional effect provides an explanation for the reduction in cardiovascular events that is attributed to the consumption of green tea.

ROS participate in cellular signaling transduction and regulate a number of important cellular events (Rich and McLaughlin 2003). Oxidative stress and ROS up-regulate the production of proinflammatory cytokines such as IL-6 and CRP through activating the transcription nuclear factor κB (NF-κB) to participate in atherogenesis (Himmelfarb 2004). Moreover, CRP itself upregulates NF-κB, thereby constituting a positive feedback loop that contributes to ongoing proatherosclerotic risk (Verma et al. 2003). Our results demonstrated that ECGC inhibits the Ang II-induced generation of O_2^- and ROS in VSMCs. This suggests that EGCG is able to reduce IL-6- and Ang II-induced CRP production in VSMCs, possibly via a direct inhibitory effect and an indirect effect related to interference with O_2^- and ROS generation.

Conclusion

The results indicate that EGCG has the ability to produce an anti-inflammatory effect via inhibiting IL-6- and Ang II-induced CRP accumulation, as well as Ang II-induced O_2^- and ROS generation in VSMCs. It is noteworthy that the results provide a new insight into the pharmacological basis of EGCG for cardiovascular diseases. However, it remains to be investigated whether EGCG also suppresses the generation of other inflammatory mediators in VSMCs.

References

Bass DA, Parce JW, Dechatelet LR, Szejda P, Seeds MC, Thomas M. Flow cytometric studies of oxidative product formation by neutrophils: a graded response to membrane stimulation. Journal of Immunology 130 (4), 1910–1917, 1983.

Calabró P, Willerson JT, Yeh ETH. Inflammation cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108 (16), 1930–1932, 2003.

Cheng XW, Masafunmi K, Kae N, Liu Z, Di Q, Hasegawa J, Iwata M, Murohara T, Yokota M, Iguchi A. Mechanisms of the inhibitory effect of epigallocatechin-3-gallate on cultured human vascular smooth muscle cell invasion. Arteriosclerosis, Thrombosis, and Vascular Biology 25 (9), 1864–1870, 2005.

Chyu KY, Babbidge SM, Zhao X, Dandillaya R, Rietveld AG, Yano J, Dimayuga P, Cercek B, Shah PK. Differential effects of green tea-derived catechin on developing versus established atherosclerosis in apolipoprotein E-null mice. Circulation 109 (20), 2448–2453, 2004.

Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GDO, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation

in the prediction of coronary heart disease. New England Journal of Medicine 350 (14), 1387–1397, 2004.

Griendling KK, Taubman MB, Akers M, Mendlowitz M, Alexander RW. Characterization of phosphatidylinositol-specific phospholipase C from cultured vascular smooth muscle cells. Journal of Biological Chemistry 266 (23), 15498–15504, 1991.

Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circulation Research 86 (5), 494–501, 2000.

Hattori Y, Matsumura M, Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovascular Research 58 (1), 186–195, 2003.

Himmelfarb J. Linking oxidative stress and inflammation in kidney disease: which is the chicken and which is the egg? Seminars in Dialysis 17 (6), 449–454, 2004.

Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 44 (1), 6–11, 2004.

Koenig W. Predicting risk and treatment benefit in atherosclerosis: the role of C-reactive protein. International Journal of Cardiology 98 (2), 199–206, 2005.

L'Allemain G. Multiple actions of EGCG, the main component of green tea. Bulletin du Cancer 86 (9), 721–724, 1999.

Li R, Peng N, Du F, Li XP, Le WD. Epigallocatechin gallate protects dopaminergic neurons against 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity by inhibiting microglial cell activation. Nan Fang Yi Ke Da Xue Xue Bao 26 (4), 376–380, 2006.

Libby P. Inflammation in atherosclerosis. Nature 420 (6917), 868–874, 2002.

Miura Y, Chiba T, Miura S, Tomita I, Umegaki K, Ikeda M, Tomita T. Green tea polyphenols (flavan 3-ols) prevent oxidative modification of low density lipoproteins: an ex vivo study in humans. Journal of Nutritional Biochemistry 11 (4), 216–222, 2000.

Ouyang P, Peng WL, Lai WY, Xu AL. Green tea polyphenols inhibit low-density lipoprotein-induced proliferation of rat vascular smooth muscle cells. Di Yi Jun Yi Da Xue Xue Bao 24 (9), 975–979, 2004.

Peng N, Liu JT, Gao DF, Lin R, Li R. Angiotensin II-induced C-reactive protein generation: inflammatory role of vascular smooth muscle cells in atherosclerosis. Atherosclerosis 193 (2), 292–298, 2007.

Ramesh E, Geraldine P, Thomas PA. Regulatory effect of epigallocatechin gallate on the expression of C-reactive protein and other inflammatory markers in an experimental model of atherosclerosis. Chemico-Biological Interactions 183 (1), 125–132, 2010.

Rich S, McLaughlin VV. Endothelin receptor blockers in cardiovascular disease. Circulation 108 (18), 2184–2190, 2003.

Verma S, Badiwala MV, Weisel RD, Li SH, Wang CH, Fedak PW, Li RK, Mickle DA. C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. Journal of Thoracic and Cardiovascular Surgery 126 (6), 1886–1891, 2003.

Wei IH, Wu YC, Wen CY, Shieh JY. Green tea polyphenol (−)-epigallocatechin gallate attenuates the neuronal NADPH-d/nNOS expression in the nodose ganglion of acute hypoxic rats. Brain Research 999 (1), 73–80, 2004.

Zaveri NT. Green tea and its polyphenolic catechins: medicinal uses in cancer and noncancer applications. Life Sciences 78 (18), 2073–2080, 2006.